Friday, June 19, 2026

pharma · Migraine · Narcolepsy

H. Lundbeck A/S

H. Lundbeck A/S clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN HQ
112 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Postboks 361, LYSAKER, Bærum 1326, NO, Valby, CN
Employees
112
Programs
17
Drugs
14
Patents
0
Intelligence · Clinical Programs

H. Lundbeck A/S projects

5 ClinicalTrials.gov programs sponsored by H. Lundbeck A/S.

H. Lundbeck A/S has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 20453A

    H. Lundbeck A/S

    Active, moderate-to-severe TED

    phase 1 other active

    1 trial
  2. 20653A

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial
  3. 21117A

    H. Lundbeck A/S

    Narcolepsy

    phase 1 other active

    1 trial
  4. Lu AF28996

    H. Lundbeck A/S

    Parkinson Disease

    phase 1 small molecule active

    1 trial
  5. Lu AF28996 in Patients With Parkinson's Disease

    H. Lundbeck A/S

    Parkinson's Disease

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does H. Lundbeck A/S have?

5 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.